These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12192052)

  • 1. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.
    So CW; Cleary ML
    Mol Cell Biol; 2002 Sep; 22(18):6542-52. PubMed ID: 12192052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common mechanism for oncogenic activation of MLL by forkhead family proteins.
    So CW; Cleary ML
    Blood; 2003 Jan; 101(2):633-9. PubMed ID: 12393557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.
    DiMartino JF; Ayton PM; Chen EH; Naftzger CC; Young BD; Cleary ML
    Blood; 2002 May; 99(10):3780-5. PubMed ID: 11986236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
    DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
    Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.
    So CW; Lin M; Ayton PM; Chen EH; Cleary ML
    Cancer Cell; 2003 Aug; 4(2):99-110. PubMed ID: 12957285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23).
    Borkhardt A; Repp R; Haas OA; Leis T; Harbott J; Kreuder J; Hammermann J; Henn T; Lampert F
    Oncogene; 1997 Jan; 14(2):195-202. PubMed ID: 9010221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.
    Ayton PM; Cleary ML
    Oncogene; 2001 Sep; 20(40):5695-707. PubMed ID: 11607819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain.
    Goto NK; Zor T; Martinez-Yamout M; Dyson HJ; Wright PE
    J Biol Chem; 2002 Nov; 277(45):43168-74. PubMed ID: 12205094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The small oligomerization domain of gephyrin converts MLL to an oncogene.
    Eguchi M; Eguchi-Ishimae M; Greaves M
    Blood; 2004 May; 103(10):3876-82. PubMed ID: 14751928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.
    Ono R; Nakajima H; Ozaki K; Kumagai H; Kawashima T; Taki T; Kitamura T; Hayashi Y; Nosaka T
    J Clin Invest; 2005 Apr; 115(4):919-29. PubMed ID: 15761502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
    Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
    Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment.
    Wang F; Marshall CB; Yamamoto K; Li GY; Gasmi-Seabrook GM; Okada H; Mak TW; Ikura M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6078-83. PubMed ID: 22474372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.
    Lavau C; Du C; Thirman M; Zeleznik-Le N
    EMBO J; 2000 Sep; 19(17):4655-64. PubMed ID: 10970858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.
    Ayton PM; Chen EH; Cleary ML
    Mol Cell Biol; 2004 Dec; 24(23):10470-8. PubMed ID: 15542854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein.
    Xia ZB; Anderson M; Diaz MO; Zeleznik-Le NJ
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8342-7. PubMed ID: 12829790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FEL (AF-4) protein donates transcriptional activation sequences to Hrx-Fel fusion proteins in leukemias containing T(4;11)(Q21;Q23) chromosomal translocations.
    Morrissey JJ; Raney S; Cleary ML
    Leuk Res; 1997 Oct; 21(10):911-7. PubMed ID: 9403001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.
    Ayton PM; Cleary ML
    Genes Dev; 2003 Sep; 17(18):2298-307. PubMed ID: 12952893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.
    Birke M; Schreiner S; García-Cuéllar MP; Mahr K; Titgemeyer F; Slany RK
    Nucleic Acids Res; 2002 Feb; 30(4):958-65. PubMed ID: 11842107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias.
    Ma C; Staudt LM
    Blood; 1996 Jan; 87(2):734-45. PubMed ID: 8555498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX.
    Slany RK; Lavau C; Cleary ML
    Mol Cell Biol; 1998 Jan; 18(1):122-9. PubMed ID: 9418860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.